ReviewAdvanced drug delivery reviews2013
Structure and dynamics of drug carriers and their interaction with cellular receptors: focus on serum transferrin.
Review in Advanced drug delivery reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Molecular mimicry of the receptor-binding domain of the SARS-CoV-2 spike protein: from the interaction of spike-specific antibodies with transferrin and lactoferrin to the antiviral effects of human recombinant lactoferrin.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023Article
- Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems.Drug delivery · 2022Review
- Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies.Journal of hematology & oncology · 2022Review
- Drug-loaded PEG-PLGA nanoparticles for cancer treatment.Frontiers in pharmacology · 2022Review
- Interaction between DNA, Albumin and Apo-Transferrin and Iridium(III) Complexes with Phosphines Derived from Fluoroquinolones as a Potent Anticancer Drug.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges.Pharmaceutics · 2021Review
- A Rapid Dual-Responsive Releasing Nano-Carrier by Decomposing the Copolymer and Reversing the Core Dissolution.Frontiers in bioengineering and biotechnology · 2021Article
- Establishment of a hTfR mAb-functionalized HPPS theranostic nanoplatform.Nanotheranostics · 2020Article
- NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry.Molecules (Basel, Switzerland) · 2019Review
- Protein-Polymer Conjugates Synthesized Using Water-Soluble Azlactone-Functionalized Polymers Enable Receptor-Specific Cellular Uptake toward Targeted Drug Delivery.Bioconjugate chemistry · 2019Article
- Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry.Annual review of nutrition · 2018Review
- Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy.International journal of nanomedicine · 2018Article
- A Transferrin-Conjugated Hollow Nanoplatform for Redox-Controlled and Targeted Chemotherapy of Tumor with Reduced Inflammatory Reactions.Theranostics · 2018Article
- Evaluation of Gallium as a Tracer of Exogenous Hemoglobin-Haptoglobin Complexes for Targeted Drug Delivery Applications.Journal of the American Society for Mass Spectrometry · 2016Article
- Immune response after intermittent minimally invasive intraocular pressure elevations in an experimental animal model of glaucoma.Journal of neuroinflammation · 2016Article
- NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer?Journal of nanobiotechnology · 2016Review
- Evaluation of Nonferrous Metals as Potential In Vivo Tracers of Transferrin-Based Therapeutics.Journal of the American Society for Mass Spectrometry · 2016Article
- Increased brain uptake of targeted nanoparticles by adding an acid-cleavable linkage between transferrin and the nanoparticle core.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Engineering an Anti-Transferrin Receptor ScFv for pH-Sensitive Binding Leads to Increased Intracellular Accumulation.PloS one · 2015Article
- Humanized HLA-DR4.RagKO.IL2RγcKO.NOD (DRAG) mice sustain the complex vertebrate life cycle of Plasmodium falciparum malaria.Malaria journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Highly proliferative cells have a dramatically increased need for iron which results in the expression of an increased number of transferrin receptors (TFR). This insight makes the transferrin receptor on these cells an excellent candidate for targeted therapeutics. In this regard, it is critical to understand at a molecular level exactly how the TFR interacts with its ligand, hTF. Understanding of the hTF/TFR pathway could, in theory, maximize the use of this system for development of more effective small molecules or toxin-conjugates to specifically target cancer cells. Many strategies have been attempted with the objective of utilizing the hTF/TFR system to deliver drugs; these include conjugation of a toxin or drug to hTF or direct targeting of the TFR by antibodies. To date, in spite of all of the effort, there is a conspicuous absence of any successful candidate drugs reaching the clinic. We suggest that a lack of quantitative data to determine the basic biochemical properties of the drug carrier and the effects of drug-conjugation on the hTF-TFR interaction may have contributed to the failure to realize the full potential of this system. This review provides some guidelines for developing a more quantitative approach for evaluation of current and future hTF-drug conjugates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.